Highlights• Investigators have discovered a cocktail of chemicals which, when added to stem cells in a precise order, turns on genes found in kidney cells in the same order that they turn on during embryonic kidney development.• The kidney cells continued to behave like kidney cells when transplanted into adult or embryonic mouse kidneys.
Newswise — Washington, DC (December 19, 2013) — Researchers have successfully coaxed stem cells to become kidney tubular cells, a significant advance toward one day using regenerative medicine, rather than dialysis and transplantation, to treat kidney failure. The findings are published in the Journal of the American Society of Nephrology (JASN).
Chronic kidney disease is a major global public health problem, and when patients progress to kidney failure, their treatment options are limited to dialysis and kidney transplantation. Regenerative medicine—which involves rebuilding or repairing tissues and organs—may offer a promising alternative.
Albert Lam, MD, Benjamin Freedman, PhD, Ryuji Morizane, MD, PhD (Brigham and Women’s Hospital), and their colleagues have been working for the past five years to develop strategies to coax human pluripotent stem cells—particularly human embryonic stem (ES) cells and human induced pluripotent stem (iPS) cell—into kidney cells for the purposes of kidney regeneration.
“Our goal was to develop a simple, efficient, and reproducible method of differentiating human pluripotent stem cells into cells of the intermediate mesoderm, the earliest tissue in the developing embryo that is fated to give rise to the kidneys,” said Dr. Lam. He noted that these cells would be the “starting blocks” for deriving more specific kidney cells.
The researchers discovered a cocktail of chemicals which, when added to stem cells in a precise order, causes them to turn off genes found in ES cells and turn on genes found in kidney cells, in the same order that they turn on during embryonic kidney development. The investigators were able to differentiate both human ES cells and human iPS cells into cells expressing PAX2 and LHX1, two key markers of the intermediate mesoderm. The iPS cells were derived by transforming fibroblasts obtained from adult skin biopsies to pluripotent cells, making the techniques applicable to personalized approaches where the starting cells can be derived from skin cells of a patient. The differentiated cells expressed multiple genes expressed in intermediate mesoderm and could spontaneously give rise to tubular structures that expressed markers of mature kidney tubules. The researchers could then differentiate them further into cells expressing SIX2, SALL1, and WT1, important markers of the metanephric cap mesenchyme, a critical stage of kidney differentiation. In kidney development, the metanephric cap mesenchyme contains a population of progenitor cells that give rise to nearly all of the epithelial cells of the kidney.
The cells also continued to behave like kidney cells when transplanted into adult or embryonic mouse kidneys, giving hope that investigators might one day be able to create kidney tissues that could function in a patient and would be 100% immunocompatible.
“We believe that the successful derivation of kidney progenitor cells or functional kidney cells from human pluripotent stem cells will have an enormous impact on a variety of clinical and translational applications, including kidney tissue bioengineering, renal assist devices to treat acute and chronic kidney injury, drug toxicity screening, screening for novel therapeutics, and human kidney disease modeling,” said Dr. Lam.
Study co-authors include Paul Lerou, MD, M. Todd Valerius, PhD, and Joseph Bonventre, MD, PhD (senior author).
Disclosures: The authors reported no financial disclosures. The study was supported by funds from the National Institutes of Health and the American Heart Association.
The article, entitled “Rapid and Efficient Differentiation of Human Pluripotent Stem Cells into Intermediate Mesoderm that Forms Tubules Expressing Kidney Proximal Tubular Markers,” will appear online at http://jasn.asnjournals.org/ on December 19, 2013.
The content of this article does not reflect the views or opinions of The American Society of Nephrology (ASN). Responsibility for the information and views expressed therein lies entirely with the author(s). ASN does not offer medical advice. All content in ASN publications is for informational purposes only, and is not intended to cover all possible uses, directions, precautions, drug interactions, or adverse effects. This content should not be used during a medical emergency or for the diagnosis or treatment of any medical condition. Please consult your doctor or other qualified health care provider if you have any questions about a medical condition, or before taking any drug, changing your diet or commencing or discontinuing any course of treatment. Do not ignore or delay obtaining professional medical advice because of information accessed through ASN. Call 911 or your doctor for all medical emergencies.
Founded in 1966, and with more than 14,000 members, the American Society of Nephrology (ASN) leads the fight against kidney disease by educating health professionals, sharing new knowledge, advancing research, and advocating the highest quality care for patients.